Drug Industry – Talk Bio

Bayer’s BlueRock Lays Off 50 Employees, Shuts Cambridge Labs in Streamlining Move

5 days ago talkbio0Tagged Bayer, bemdaneprocel, BlueRock Therapeutics, Cambridge research labs, Cell Therapy, Drug Industry, layoffs

BlueRock Therapeutics; Bayer; layoffs; biotech; Cambridge research labs; cell therapy; streamlining; bemdaneprocel; OpCT-001; pharmaceutical industry

Inside the FDA’s Listening Tour: Officials Agree US Lags Behind China on Drug Development

2 weeks ago talkbio0Tagged Biotechnology, China, Clinical Trials, Drug Development, Drug Industry, innovation, Regulation, United States Food and Drug Administration

FDA; China; drug development; biotechnology; regulation; clinical trials; pharmaceutical industry; biotech innovation

Sage Therapeutics Acquired by Supernus Pharmaceuticals in $561M Deal

2 weeks ago talkbio0Tagged Acquisition, Biogen, Deal Value, Depression, Postpartum, Drug Industry, Supernus Pharmaceuticals, Zurzuvae

Sage Therapeutics; Supernus Pharmaceuticals; acquisition; Zurzuvae; postpartum depression; biotech; pharmaceutical industry; major depressive disorder; Biogen; deal value

AstraZeneca Signs $110M AI-Driven R&D Deal with CSPC Pharmaceutical for Chronic Disease Drugs

3 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, AstraZeneca, China pharma, Chronic disease, Collaboration, Dosage Forms, Drug Discovery, Drug Industry, GZMH gene, Immune System Diseases, milestone payments, oral therapies

AstraZeneca; CSPC Pharmaceutical; AI drug discovery; chronic diseases; immunological diseases; oral therapies; R&D collaboration; China pharma; milestone payments; pharmaceutical industry

Recursion and Genentech Announce Significant Staff Layoffs in 2025

3 weeks ago talkbio0Tagged Biotech Layoffs, Drug Industry, genentech, pipeline cutbacks, Recursion

Recursion Pharmaceuticals; Genentech; biotech layoffs; workforce reduction; pipeline cutbacks; biotech funding; pharmaceutical industry; 2025 layoffs

GSK Appoints Sanofi Veteran to Lead Vaccines R&D; Leadership Change at Bristol Myers Corporate Affairs

4 weeks ago talkbio0Tagged affairs, Corporate, Drug Industry, executive appointment, Gurunathan, Leadership Change, Myers, R&D, Sanjay, sanofi, SmithKline Beecham, squibb, Vaccines

GSK; Sanofi; vaccine R&D; Sanjay Gurunathan; leadership change; pharmaceutical industry; Bristol Myers Squibb; corporate affairs; executive appointment

Eli Lilly Acquires SiteOne for Up to $1B to Expand Non-Opioid Pain Pipeline

1 month ago talkbio0Tagged Acquisition, Chronic pain, Drug Industry, eli lilly, Nav1.8 inhibitor, neuroscience pipeline, non-opioid pain treatment, SiteOne Therapeutics, STC-004

Eli Lilly; SiteOne Therapeutics; non-opioid pain treatment; STC-004; acquisition; Nav1.8 inhibitor; chronic pain; neuroscience pipeline; Vertex; pharmaceutical industry

Exit Strategy: Biopharma Professionals Consider Opportunities Outside Industry and US

1 month ago talkbio0Tagged Biological Science Disciplines, Biopharma, biopharma survey, biotech careers, Drug Industry, employment, Industry, Market, Transition Mutation, trends qualifier, U.S.

biopharma talent; job market trends; industry transition; employment outside US; biopharma survey 2025; life sciences employment; biotech careers; pharmaceutical industry

HHS: All Branded Drugs Without Generic or Biosimilar Competition Must Abide by MFN Order Across All Markets

1 month ago talkbio0Tagged biosimilar competition, branded drugs, CHARGE Syndrome, Country, Drug Industry, drug price, executive order, Generic competition, most-favored, Organisation for Economic Co-Operation and Development

most-favored nation pricing; branded drugs; generic competition; biosimilar competition; HHS; executive order; drug pricing; pharmaceutical industry; OECD countries

Pharma Companies Eye ‘First Sale’ Rule to Lessen Tariff Costs Amid New US Trade Measures

1 month ago talkbio0Tagged customs loophole, drug import duties, Drug Industry, first, minimis exemption, sale rule, tariff avoidance, trade compliance, Trump administration, U.S., US tariffs

first sale rule; pharmaceutical industry; US tariffs; customs loophole; drug import duties; tariff avoidance; trade compliance; Trump administration; de minimis exemption